Vinorelbine combined with a protracted course of temozolomide for recurrent brain Metastases: a phase I trial
- 14 April 2006
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 78 (3), 277-280
- https://doi.org/10.1007/s11060-005-9095-8
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002New England Journal of Medicine, 2005
- Risks and Benefits of Phase 1 Oncology Trials, RevisitedNew England Journal of Medicine, 2005
- Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: A phase II randomized trialInternational Journal of Radiation Oncology*Biology*Physics, 2005
- One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastomaNeurology, 2004
- Brain metastasesCurrent Neurology and Neuroscience Reports, 2004
- Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II studyCancer Chemotherapy and Pharmacology, 2003
- Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesBritish Journal of Cancer, 2003
- First-Line Chemotherapy with Vinorelbine, Gemcitabine, and Carboplatin in the Treatment of Brain Metastases from Non-Small-Cell Lung Cancer: A Phase II StudyCancer Investigation, 2002
- Concomitant brain radiotherapy and vinorelbine–ifosfamide–cisplatin chemotherapy in brain metastases of non-small cell lung cancerLung Cancer, 1999
- Modification of the blood-brain barrier permeability by vinorelbine:effect of intracarotid infusion compared with intravenous infusionAnti-Cancer Drugs, 1996